Theralink Technologies, Inc

At Theralink Technologies, our approach is based on more than 16 years of research and development. Our research indicates that genomic and transcriptomic information alone provides an incomplete information resource for physicians to make patient-specific treatment decisions. Our phosphoproteomic RPPA approach is the only commercial platform that quantifies the activation state (phosphorylation) of drug target proteins and their downstream signaling partners within the tumor tissue. Our advanced technology exploits our understanding of the drug-receptor and drug-protein interactions that drive treatment responses. The Theralink assay has been developed to provide physicians with a treatment decision support tool to assist in selecting...

Precision medicine,oncology,proteomics,diagnostics,laser capture microdissection,reverse phase protein arrays,and contract research

Theralink technologies, inc operates in the Biotechnology research industry.

Theralink technologies, inc's revenue is < 1m

Theralink technologies, inc has 11 - 50 employees.